Evidence map›Paper›PMID 42189441›Full record

ArticleAnnals of surgical oncology2026

The Role of Adjuvant Primary Site Radiotherapy for Cutaneous Melanoma Patients with Microsatellitosis.

Anjali Devireddy, Yifan Yi, Kelsey N Nordlund, Ruitao Lin, Aya Salem, Noel X Yang, Sydney Keatts, Oriana Jerez, Ahsan Farooqi, Andrew J Bishop and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Anjali Devireddy *Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yifan Yi *Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kelsey N Nordlund *Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ruitao LinDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Aya SalemDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Noel X YangDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sydney KeattsDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Oriana JerezDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ahsan FarooqiDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Andrew J BishopDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
B Ashleigh GuadagnoloDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Priyadharsini NagarajanDepartment of Anatomical Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Roi WeiserDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sarah B FisherDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ryan GoepfertDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Merrick I RossDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Rodabe N AmariaDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Isabella C Glitza OlivaDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Alison K YoderDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Devarati MitraDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. dmitra@mdanderson.org.

Funding

Melanoma Research Foundation Career Development AwardRadiological Society of North America Scholar Award
6 · The paper itself

Abstract

purposeThe presence of microsatellites in cutaneous melanoma has historically been associated with a poor prognosis. Whether adjuvant primary site radiation therapy (RT) mitigates risk of recurrence is unknown.

methodsAll patients with cutaneous melanoma who underwent primary site wide local excision at our center between 2016 and 2023 with histopathologic evidence of microsatellites and no clinically involved lymph nodes, in-transit disease, or macrosatellites were retrospectively reviewed. We investigated the association of patient, disease, and treatment factors with recurrence and survival outcomes.

resultsWe identified 153 eligible patients with microsatellites. With a median follow-up of 31 months from resection, 3-year local recurrence-free survival (LRFS) was 78% and 3-year disease-free survival (DFS) was 42%. The majority received adjuvant systemic therapy (55%, n = 85 immune checkpoint inhibition; 5%, n = 7 BRAF/MEK-directed therapy). Fifty-nine patients (39%) received postoperative RT after wide local excision. On multivariate analyses with inverse propensity score weighting, receipt of adjuvant primary site RT was associated with longer local recurrence-free survival (LRFS, hazard ratio 0.22, p = 0.04), which appears to drive longer disease-free survival (DFS, hazard ratio 0.46, p = 0.007).

conclusionsIn the contemporary therapeutic era, even with the majority of patients receiving adjuvant immune checkpoint inhibition or targeted therapy, adjuvant RT is associated with higher local control and DFS. Patients with microsatellitosis should be referred for consideration of postoperative RT.

Indexed as

MelanomaMicrosatellite RepeatsNeoplasm Recurrence, LocalSkin NeoplasmsAdultAgedAged, 80 and overCutaneous Malignant MelanomaFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisRadiotherapy, AdjuvantRetrospective Studies

Identifiers

PMID42189441
PMCPMC13337811

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.